Surfactant induced glistenings: surface active ingredients in ophthalmic solutions may enhance water entry into the voids of implanted acrylic intraocular lenses.
OBJECTIVE
To investigate the light scattering properties of acrylic intraocular lenses (IOLs) placed in eyes treated with diclofenac sodium (Diclod, Wakamoto, Japan) and betamethasone phosphate (Rinderon, Shionogi, Japan) ophthalmic solutions.


METHODS
The light scattering properties of IOLs (MA30BA, Alcon laboratories) placed in 32 eyes treated with Diclod and 31 treated with Rinderon were evaluated 3 years after implantation using Scheimpflug photography.


RESULTS
The averaged intensity of glistenings was 9.0 CCT (computer compatible tapes) in the Diclod test group and 4.2 CCT in the Rinderon test group (p = 0.002). The intensity of surface light scattering for the Diclod and Rinderon test groups was 24.0 CCT and 26.9 CCT, respectively (p = 0.081).


CONCLUSIONS
The Diclod test group had a greater number of glistenings than the Rinderon test group. Both drugs have similar anti-inflammatory properties and Diclod, unlike Rinderon, also contains the surfactant polysorbate. We proposed that the presence of surfactant, or other ingredient, in commercially available eyedrops may enhance the development of glistenings.
Ayaki
Masahiko
M
Department of Ophthalmology, Fujigaoka Hospital, Showa University School of Medicine, Japan. mayaki@olive.ocn.ne.jp
Nishihara
Hitoshi
H
Yaguchi
Shigeo
S
Koide
Ryohei
R
D000180:Acrylic Resins; D000368:Aged; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000494:pharmacology*; D001623:Betamethasone / Q000494:pharmacology*; D003982:Dibekacin / Q000494:pharmacology*; D004008:Diclofenac / Q000494:pharmacology*; D005260:Female; D006801:Humans; D007910:Lenses, Intraocular; D008297:Male; D009883:Ophthalmic Solutions; D013501:Surface-Active Agents / Q000494:pharmacology*
D000180:Acrylic Resins; D000900:Anti-Bacterial Agents; D000894:Anti-Inflammatory Agents, Non-Steroidal; D009883:Ophthalmic Solutions; D013501:Surface-Active Agents; D004008:Diclofenac; D003982:Dibekacin; D001623:Betamethasone